IDRx

IDRx is a clinical-stage biopharmaceutical company focused on transforming cancer care with precision therapies. The company's approach involves developing highly potent and selective targeted therapies designed to overcome the limitations of existing precision cancer medicines. Their pipeline programs include small molecule tyrosine kinase inhibitors like IDRX-42 and IDRX-73, which aim to inhibit key genetic drivers and drug-resistant mutations in gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 and boasts a leadership team with extensive experience in drug development, having been involved in the discovery, development, and commercialization of over 10 approved drugs.

IDRx's mission is to provide patients with prolonged and durable responses to therapy, particularly in earlier lines of treatment. They are currently conducting a Phase 1/1b study of IDRX-42 for patients with GIST and have recently announced promising preliminary clinical data. The company is poised to make significant strides in the treatment of GIST and potentially other cancers as they continue to develop their innovative precision therapies.

IDRx is a virtual-first company, meaning that employees are not required to work from a traditional office setting. This allows for greater flexibility in terms of location and work schedule, though specific details about remote work options are not provided on the website.

IDRx is a virtual-first company, and they do not offer any specific employee benefits on their website. They do not accept candidate submissions from agencies unless a contract is in place.

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care by developing highly potent and selective targeted therapies. Their mission is to address the limitations of existing precision cancer medicines by creating therapies that stop key tumor escape mechanisms and prolong response to treatment. They aim to develop intelligently designed precision therapies that effectively target the full range of tumor biology, providing patients with prolonged, durable, and better tolerated therapeutic responses.

IDRx promotes a culture of innovation, collaboration, and patient focus. They are a virtual first company, emphasizing results-oriented and self-motivated individuals who are passionate about developing precision therapies for those battling cancer. Their leadership team emphasizes coaching, mentoring, and empowerment to achieve collective goals.

IDRx is a virtual-first company focused on building a diverse, equitable, and inclusive workplace. They welcome applications from individuals who are passionate about developing precision therapies for those battling cancer and are patient focused, results oriented, and self-motivated. They do not accept candidate submissions from agencies unless there is a contract in place, and any resumes sent to any employee of IDRx without a signed contract will not constitute an obligation of fee on behalf of IDRx.